Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 4/2014

01-12-2014 | Biomarkers of Heart Failure (WHW Tang, Section Editor)

Biomarkers in Pulmonary Arterial Hypertension

Authors: Julie L. Rosenthal, Miriam S. Jacob

Published in: Current Heart Failure Reports | Issue 4/2014

Login to get access

Abstract

Pulmonary hypertension prevalence continues to rise and remains a clinical dilemma with regards to patient recognition and management. Despite advances in our understanding of the pathophysiology and pathogenesis behind pulmonary hypertension (PH), this heterogeneous cohort continues to demonstrate significant morbidity and mortality. Biomarkers serve as a dynamic, noninvasive tool in a physician’s clinical armamentarium. Their role is to impact clinical decision-making and to facilitate patient education with respect to diagnosis, prognosis, and therapeutic intervention. This review will elucidate the relationship between PH and serum biomarkers related to inflammation, myocardial dysfunction or stress, and endothelial dysfunction. Over the last two decades, the utilization and incorporation of biomarkers into the evaluation and management of pulmonary hypertension has exploded. Consequently, current guidelines and consensus documents have adopted their use. The additive roles of both established and innovative biomarkers in individuals with pulmonary arterial hypertension (PAH) will be discussed.
Literature
1.
McLaughlin VV et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250–94.PubMedCrossRef
2.
Galie N et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219–63.PubMedCrossRef
3.
Hoeper MM et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50.PubMedCrossRef
4.
Simonneau G et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12):5S–12S.PubMedCrossRef
5.
Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med. 2001;22(3):385–91. vii.PubMedCrossRef
6.
7.
Torbicki A, Kurzyna M. Pulmonary arterial hypertension: evaluation of the newly diagnosed patient. Semin Respir Crit Care Med. 2005;26(4):372–8.PubMedCrossRef
8.••
McGoon MD et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25):D51–9. This is a historical overview of pulmonary hypertension.PubMedCrossRef
9.
McGoon MD et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923–31.PubMedCrossRef
10.
D’Alonzo GE et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9.PubMedCrossRef
11.
Benza RL et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–56.PubMedCrossRef
12.
Strange G et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study. Pulm Circ. 2013;3(1):89–94.PubMedCentralPubMedCrossRef
13.
14.
Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115(8):949–52.PubMedCrossRef
15.
Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J. 2010;160(4):583–94.PubMedCrossRef
16.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–36.PubMedCrossRef
17.
Benza RL et al. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant. 2007;26(5):437–46.PubMedCrossRef
18.
Currie PJ et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985;6(4):750–6.PubMedCrossRef
19.
Forfia PR et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034–41.PubMedCrossRef
20.
Vonk MC et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. Eur J Echocardiogr. 2007;8(5):317–21.PubMedCrossRef
21.
Borgeson DD et al. Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr. 1996;9(6):832–7.PubMedCrossRef
22.
Fisher MR et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–21.PubMedCentralPubMedCrossRef
23.••
McLaughlin VV et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D73–81. This article describes the goals of treatment in PH.PubMedCrossRef
24.
Vonk-Noordegraaf A et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013;62(25 Suppl):D22–33.PubMedCrossRef
25.
Mahadavan G, Nguyen TH, Horowitz JD. Brain natriuretic peptide: a biomarker for all cardiac disease? Curr Opin Cardiol. 2014;29(2):160–6.PubMedCrossRef
26.
Nagaya N et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865–70.PubMedCrossRef
27.
Hachulla E et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60(6):1831–9.PubMedCrossRef
28.
Simonneau G et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41.PubMedCrossRef
29.
Tyndall AJ et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTA R) database. Ann Rheum Dis. 2010;69(10):1809–15.
30.
Coghlan JG et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340–9.PubMedCentralPubMedCrossRef
31.
Mathai SC et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J. 2010;35(1):95–104.PubMedCrossRef
32.•
Tuder RM et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D4–D12. This article describes the pathology and biology of pulmonary hypertension.PubMedCrossRef
33.
Bogaard HJ et al. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135(3):794–804.PubMedCrossRef
34.
Fijalkowska A et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313–21.PubMedCrossRef
35.
Benza RL et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–72.PubMedCrossRef
36.
Benza RL et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354–62.PubMedCrossRef
37.
Benza RL et al. Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. Thromb Haemost. 2012;108(6):1049–60.PubMedCrossRef
38.
Munagala VK, Burnett Jr JC, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004;29(12):707–69.PubMedCrossRef
39.
Cracowski JL, Leuchte HH. The potential of biomarkers in pulmonary arterial hypertension. Am J Cardiol. 2012;110(6 Suppl):32S–8S.PubMedCrossRef
40.
Torbicki A et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003;108(7):844–8.PubMedCrossRef
41.
Filusch A et al. High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. Clin Sci (Lond). 2010;119(5):207–13.CrossRef
42.
Heresi GA et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. Eur Respir J. 2012;39(4):939–44.PubMedCrossRef
43.
Vélez-Martínez M et al. Association of cardiac troponin I with disease severity and outcomes in patients with pulmonary hypertension. Am J Cardiol. 2013;111(12):1812–7.PubMedCrossRef
44.
Mahajan VS, Jarolim P. How to interpret elevated cardiac troponin levels. Circulation. 2011;124(21):2350–4.PubMedCrossRef
45.
Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999;13(3):682–5.PubMedCrossRef
46.
Leyva F et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858–65.PubMedCrossRef
47.
48.
Nagaya N et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999;160(2):487–92.PubMedCrossRef
49.
Njaman W et al. Serum uric acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. Int Heart J. 2007;48(4):523–32.PubMedCrossRef
50.
Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol. 2006;62(6):633–44.PubMedCentralPubMedCrossRef
51.
52.
53.
Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7(10):827–40. This is a review of IL-33/ST2 pathway which elucidates the biology of ST2 biomarker and potential role in PH.PubMedCrossRef
54.
Felker GM et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circulation: Heart Failure. 2013;6(6):1172–9.PubMedCentral
55.
Zheng YG et al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin Cardiol. 2014;37(6):365–70.PubMedCrossRef
56.
Rhodes CJ et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart. 2011;97(13):1054–60.PubMedCrossRef
57.
Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2008;32(2):503–12.PubMedCrossRef
58.
Rosenberg M et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2008;1(1):43–9.PubMedCrossRef
59.
Singh K et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 1999;33(2):663–70.PubMedCrossRef
60.
Denhardt DT et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107(9):1055–61.PubMedCentralPubMedCrossRef
61.
Rosenberg M et al. Osteopontin (OPN) improves risk stratification in pulmonary hypertension (PH). Int J Cardiol. 2012;155(3):504–5.PubMedCrossRef
62.
Rosenberg M et al. Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension. Eur J Clin Invest. 2012;42(9):933–42.PubMedCrossRef
63.
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221–6.PubMedCrossRef
64.
Shlipak MG et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45(2):268–71.PubMedCrossRef
65.
Fenster BE et al. Cystatin C: a potential biomarker for pulmonary arterial hypertension. Respirology. 2014;19:583–9.PubMedCrossRef
66.
Deftereos S et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014;2(2):131–7.PubMedCrossRef
67.
Ghofrani H-AMD et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.PubMedCrossRef
68.
Barst RJ et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301.PubMedCrossRef
69.
Galie N et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9.PubMedCrossRef
Metadata
Title
Biomarkers in Pulmonary Arterial Hypertension
Authors
Julie L. Rosenthal
Miriam S. Jacob
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 4/2014
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-014-0225-5

Other articles of this Issue 4/2014

Current Heart Failure Reports 4/2014 Go to the issue

Prevention of Heart Failure (M St. John Sutton, Section Editor)

New Drugs and Devices in the Pipeline for Heart Failure with Reduced Ejection Fraction Versus Heart Failure with Preserved Ejection Fraction

Epidemiology of Heart Failure (CSP Lam, Section Editor)

Epidemiology of Pulmonary Hypertension and Right Ventricular Failure in Left Heart Failure

Epidemiology of Heart Failure (CSP Lam, Section Editor)

Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes

Epidemiology of Heart Failure (CSP Lam, Section Editor)

New Insights in (Inter)Cellular Mechanisms by Heart Failure with Preserved Ejection Fraction

Prevention of Heart Failure (M St. John Sutton, Section Editor)

Understanding the Relationship Between Readmission and Quality of Hospital Care in Heart Failure

Biomarkers of Heart Failure (WHW Tang, Section Editor)

Novel Renal Biomarkers to Assess Cardiorenal Syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits